This article needs additional citations for verification. (April 2014) (Learn how and when to remove this template message)
|Elimination half-life||26.2±0.7 (h)|
|Chemical and physical data|
|Molar mass||193.242 g/mol g·mol−1|
|3D model (JSmol)|
Methedrone (para-methoxymethcathinone, 4-methoxymethcathinone, bk-PMMA, PMMC, methoxyphedrine, 4-MeOMC) is a recreational drug of the cathinone chemical class. Chemically, methedrone is closely related to para-methoxymethamphetamine (PMMA), methylone and mephedrone. Methedrone received media attention in 2009 after the death of two young Swedish men. In both cases toxicology analysis showed methedrone was the only drug present in both men during the time of their overdose and subsequent deaths.
- 1 Discovery
- 2 Structure and reactivity
- 3 Availability
- 4 Mechanism of action
- 5 Metabolism
- 6 Efficacy and side effects
- 7 Toxicity
- 8 Health risks
- 9 Effects on animals
- 10 Legality
- 11 References
The synthesis of methedrone was first reported in 1933.
Structure and reactivity
Methedrone is a synthetic cathinone. It is related to the parent compound cathinone. Methedrone belongs to the phenethylamine family due to the presence of the cyclic group of atoms C6H5 in which six carbons bind to form a hexagonal ring with five hydrogens each bonding to a carbon and the remaining carbon bonded to an atom or group of atoms other than hydrogen.
There are no articles found about the reactivity of methedrone.
The synthesis of methedrone is described in figure 1. and can be written as the following steps.
- Bromination of 1-(4-methoxyphenyl)propan-1-one to 2-bromo-1-(4-methoxyphenyl)propan-1-one.
- A reaction with methylamine in which the 2-bromo-1-(4-methoxyphenyl)propan-1-one becomes 1-(4-methoxyphenyl)-2-(methylamino)propan-1-ol.
- The final step is a reaction with potassium permanganate.
Methedrone can be purchased legally in Europe (excluding Sweden) and in most states in the US on the Internet, but also it can also be found at head shops and other retailers. It is, along with other new or unregulated synthetic drugs and research chemicals, commonly labeled as a "bath salt".
Methedrone is a research chemical and its euphoric and stimulant properties can be abused. Similarly to MDMA it can be administered through insufflation, ingestion, smoking, rectal, and intravenous routes; however, it differs greatly in both duration and toxicity and great care should be taken when used due to the lack of medical literature available common among designer drugs.
Mechanism of action
Methedrone has been found to be a potent serotonin transporter (SERT) and norepinephrine transporter (NET) inhibitor, but a weak dopamine transporter (DAT) inhibitor. Clinically, the DAT/SERT ratio of methedrone is less than one. Other analog compounds commonly have a DAT/SERT ratio less than half, meaning unlike other MDMA-like compounds methedrone does not prefer inhibition of the NET and DAT over the SERT. The resulting lack of inhibition despite its proclivity to release DAT can lead to a life-threatening adrenergic storm. Methedrone's high selectivity for SERT places it among the highest selectivity when compared to structurally similar compounds.
Methedrone induces the transportation mediated release of NE, DA and 5-HT from cells preloaded with monoamines making it a serotonin-norepinephrine-dopamine (SNDRA) releasing agent, also known as triple releasing agent (TRA), which is a common characteristic among drugs of abuse.
It has been found that methedrone is similar to MDMA in terms of the monoamine transporter interactions but an in vivo study of the drug resulted in a stronger hyperthermic reaction than what is normally reported in studies of MDMAs. Methedrone's affects on the serotonin transporter, SERT, can interfere and cause complications in individuals co-administrating with serotonin altering medications such as selective serotonin reuptake inhibitors (SSRIs).
To consider how methedrone (4-MeOMC) acts in a biological system, it is necessary to study the stability in an aqueous solution. Because, when tested directly in blood or urine, it is not known whether the compound will be degraded by enzymes available in the biological solutions or cause the chemical mechanisms, such as pH or dissolved oxygen. The length of the half-life of the compound has been examined and the percent remaining after 12 hours in buffers with various pHs. The tested pHs were 4, 7, 10 and 12.
The conclusions are that methedrone, just as most analogs, is stable in acid solutions. However, in neutral and basic solutions it is decomposed, where a stronger decomposing takes place as the solution turns more basic.
When comparing methdrone with its analogs, it has been found that there are several factors which affect their stability:
- The substituted group on the benzene ring.
- The groups attached at the nitrogen atom, but this is not applicable for methedrone.
Methedrone and four other analogs have their groups substituted in the meta- or para-positions. For these compounds the rate constant, k, has been determined and a Hammett plot was constructed by plotting the decomposition rate constant (0.693/half-life) in the pH of 12 against their Hammett constants, taken from literature. This again shows that methedrone is a relatively stable compound even in basic solution.
Another conclusion based on the results from the literature is that there is negative charge built up in the transition state during the rate determining step. This reasoning is based on the good linear correlation (r=0.9805) and the positive slope (determined as 1.76).
There are two possible metabolites known for methedrone:
- The carbon between the nitrogen group and R1, an H-atom in case of methedrone, will be replaced. This will lead to a smaller compound.
- The methylgroup bound to the oxygen at the benzene group will be replaced by an H-atom. This metabolite will lose the epoxide and turn into a hydroxy-compound.
Efficacy and side effects
In pharmacology, efficacy (Emax) is a term used to describe the maximum response achievable from a drug. There is little information available on Methedrone and its efficacy. According to users, the doses of Methedrone vary from 50 to 500 mg with a duration of effects range from 45 minutes to two hours. There are two cases known of fatal intoxications with Methedrone. In the first case, the postmortem femoral blood sample of the patient contained a concentration of 8.4 µg/g Methedrone, the patient died after 16 hours (but other compounds such as diazepam were also detected in his blood). In the second case the concentration of Methedrone in the postmortem femoral blood sample was 9.6 µg/g and methedrone was the only toxic compound detected. Recent studies to these fatal cases suggest that the Methedrone alone was responsible for these deaths and that the concentrations in the femoral blood represent the fatal levels of methedrone. Also, these studies show that there is little window range between a fatal dose and a non-fatal dose, this means that the safety gap is small. A fatal dose is more than 8 µg/g whereas the dose among the living cases which were studied varied from 0.1 to 4.8 µg/g blood. Knowing this, it is concluded that the dose of efficacy of Methedrone is around 8 µg/g blood, leading to death.
Anecdotal and case reports of human use of "bath salts", such as methedrone, suggest that these substances produce powerful psychological effects. These psychological effects include psychotic behavior, paranoia, delusions, hallucinations and also self-injury. There is very little known of the physical effects of methedrone in humans, but there have been some studies to the effects of methedrone in animals, so we[who?] focused on the effects in mice. Studies to the effects of Methedrone in mice show that Methedrone produces a significant increase in circling, beam breaks and hyperactivity. Furthermore, the mice also showed a significant increase in salivation, head weaving and stimulation. Methedrone is currently a legal drug in many jurisdictions, however studies show that it shares major pharmacological properties with drugs that have been banned, such as mephedrone and methylone. Also, the effects of Methedrone are very similar to the effects of banned drugs in mice. This suggests that Methedrone may be just as harmful as most commonly found Illicit drugs.
There is little research regarding the toxicity of methedrone. Research has been done by animal-testing on mice once. Also, the lethal doses found in the two Swedish methedrone-victims have been compared to the methedrone concentrations in the blood of two other males dying in similar conditions.
The mean of the methedrone concentrations in the blood of the two deceased was 1.3 μg/g blood. One of these victims had a very high concentration of Methedrone in the blood, approximately 4.8 μg/g blood. The mean of the concentrations found in the blood of the deceased victims was 8.0 μg/g blood. None of the non-lethal doses or lethal doses is known, suggesting that the safety gap between a lethal and non-lethal dose of methedrone is probably very small, thus making use of this drug dangerous because poisonings, and simultaneously death, are accidental.
In a study of the effects of synthetic cathiones in ‘bath salts’ the effects of methedrone on mice were tested, these effects were compared to the effects of cocaine and methamphetamine. Different tests were performed to get insight into motor coordination, balance and overall behavioral effects. The mice did not show any difference in motor coordination or balance (doses administered were 10.0 mg/kg and 30.0 mg/kg). However significant changes were shown in overall behavioral effects. Administration of methedrone led to:
- Increase of repeated movement of the mouse in a circular manner
- Excessive salivation
- Increase of head weaving
- Increase of stimulation, tense body
These effects are related with addiction potential. Excessive salivation is not an effect that is typically reported in humans. It is suggested that methedrone increases salivation via brain systems that primarily regulate autonomic responses.
Compared with mephedrone, methylenedioxypyrovalerone (MDPV) and 4-fluoromethcathinone (4-FMC), methedrone has a relatively slow onset. Thereby increasing the risk; because effects are not immediately shown, this could lead to an accidental overdose. It could also make the drug less popular, because humans tend to favor drugs that cause large, rapid initial increases in locomotor activity.
Even in comparison with acute toxicity, chronic toxicity is poorly researched. Only the post-mortem study did little investigation on this subject. The findings of this study only showed that hair of the deceased victims contained methedrone, however, no conclusions were made regarding these findings.
No studies have examined the effect of methedrone-use during or before pregnancy by a pregnant female on the embryo, nor is the carcinogenicity researched.
The health risks associated with methedrone are mostly unknown, but are expected to be similar to other cathinones. Methedrone was almost immediately withdrawn from sale by initial vendors after reports of adverse health effects. Some amphetamine analogs containing a para-methoxy group are known to cause severe hyperthermia and even death due to concurrent MAOI and monoamine releasing action.
Both were comatose when found. One suffered cardiorespiratory arrest on the way to the hospital, while the second survived for 16 hours in the emergency department.
Effects on animals
Methedrone has been found to have an effect on the overall behavior of mice which includes:
- Excessive salivation
- Increase of head weaving
- Increase of repeated movement of the mouse in a circular manner
- Increase of stimulation, tense body
Its sale has been banned in Sweden since December 9, 2009.
It is a controlled substance in China since October 1, 2015.
- "Ustawa z dnia 15 kwietnia 2011 r. o zmianie ustawy o przeciwdziałaniu narkomanii (Dz.U. 2011 nr 105 poz. 614)". Internetowy System Aktów Prawnych. Retrieved 17 June 2011.
- "Cathinone and its analogues (e.g. mephedrone, methedrone, α- pyrrolidinovalerophenone)". World Anti-Doping Agency. Archived from the original on 2014-11-06.
- Wikström, Maria; Thelander, Gunilla; Nyström, Ingrid; Kronstrand, Robert (2010). "Two fatal intoxications with the new designer drug methedrone (4-methoxymethcathinone)". Journal of Analytical Toxicology. 34 (9): 594–598. doi:10.1093/jat/34.9.594. ISSN 1945-2403. PMID 21073814.
- "EMCDDA and Europol step up information collection on mephedrone". Drugnet Europe (online 69). January–March 2010. Retrieved May 21, 2018.
- Skita, A. (1933). "Eine neue Synthese von 1.2-Amino-ketonen". Chemische Berichte. 66: 858–866. doi:10.1002/cber.19330660615.
- "EMCDDA - Synthetic cathinones profile (chemistry, effects, other names, synthesis, mode of use, pharmacology, medical use, control status)". europa.eu.
- /Methedrone_Tech_Prof_EMCDDA_Mar_2010.pdf "TECHNICAL PROFILE OF METHEDRONE" Check
|url=value (help) (PDF). European Monitoring Centre for Drugs and Drug Addiction. Retrieved March 17, 2015.
- Paillet-Loilier, Magalie; Cesbron, Alexandre; Le Boisselier, Reynald; Bourgine, Joanna; Debruyne, Danièle (2014). "Emerging drugs of abuse: current perspectives on substituted cathinones". Substance Abuse and Rehabilitation. 5: 37–52. doi:10.2147/SAR.S37257. ISSN 1179-8467. PMC 4043811. PMID 24966713.
- Schifano, Fabrizio; Albanese, Antonio; Fergus, Suzanne; Stair, Jackie L.; Deluca, Paolo; Corazza, Ornella; Davey, Zoe; Corkery, John; Siemann, Holger (2011). "Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues". Psychopharmacology. 214 (3): 593–602. doi:10.1007/s00213-010-2070-x. ISSN 1432-2072. PMID 21072502.
- DEA (Drug Enforcement Agency). Synthetic cathinones – DEA request for information posted 3/31/11; 2011 [retrieved 28.07.11].
- Psychonaut Research Web Mapping Project, MDPV report, London, UK: Institute of Psychiatry, King's College London; 2009.
- Yu, H.; Rothman, R. B.; Dersch, C. M.; Partilla, J. S.; Rice, K. C. (2000). "Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters". Bioorganic & Medicinal Chemistry. 8 (12): 2689–2692. ISSN 0968-0896. PMID 11131159.
- Tsujikawa, Kenji; Mikuma, Toshiyasu; Kuwayama, Kenji; Miyaguchi, Hajime; Kanamori, Tatsuyuki; Iwata, Yuko T.; Inoue, Hiroyuki (2012). "Degradation pathways of 4-methylmethcathinone in alkaline solution and stability of methcathinone analogs in various pH solutions". Forensic Science International. 220 (1–3): 103–110. doi:10.1016/j.forsciint.2012.02.005. ISSN 1872-6283. PMID 22402273.
- Mueller, Daniel M.; Rentsch, Katharina M. (2012). "Generation of metabolites by an automated online metabolism method using human liver microsomes with subsequent identification by LC-MS(n), and metabolism of 11 cathinones". Analytical and Bioanalytical Chemistry. 402 (6): 2141–2151. doi:10.1007/s00216-011-5678-8. ISSN 1618-2650. PMID 22231510.
- Marusich, Julie A.; Grant, Kateland R.; Blough, Bruce E.; Wiley, Jenny L. (2012). "Effects of synthetic cathinones contained in "bath salts" on motor behavior and a functional observational battery in mice". Neurotoxicology. 33 (5): 1305–1313. doi:10.1016/j.neuro.2012.08.003. ISSN 1872-9711. PMC 3475178. PMID 22922498.
- Calabrese, Edward J. (2008). "Addiction and dose response: the psychomotor stimulant theory of addiction reveals that hormetic dose responses are dominant". Critical Reviews in Toxicology. 38 (7): 599–617. doi:10.1080/10408440802026315. ISSN 1547-6898. PMID 18709568.
- Wise, R. A.; Bozarth, M. A. (1987). "A psychomotor stimulant theory of addiction". Psychological Review. 94 (4): 469–492. ISSN 0033-295X. PMID 3317472.
- Prosser JM, Nelson LS (2012). "The toxicology of bath salts: a review of synthetic cathinones". J Med Toxicol. 8 (1): 33–42. doi:10.1007/s13181-011-0193-z. PMC 3550219. PMID 22108839.
- Becker J, Neis P, Rohrich J, Zorntlein S (2003). "A fatal paramethoxymethamphetamine intoxication". Legal Medicine (Tokyo). 5 (Suppl 1): S138–41. doi:10.1016/s1344-6223(02)00096-2. PMID 12935573.
- "Two die of legal drug overdose". The Local. Stockholm. 14 October 2009. Retrieved 21 May 2018.
- "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.